This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Lowers Guidance
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2017 adjusted earnings per share (EPS) of $2.13, up 6% year over year.
Boston Scientific (BSX) Misses on Q1 Earnings, Updates View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.
Varian Medical (VAR) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 89 cents per share in the second quarter of fiscal 2017, which beat the Zacks Consensus Estimate by a penny.
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.
Integra LifeSciences (IART) Misses Q1 Earnings, Retains View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 64 cents in the first quarter of 2017
Edwards Lifesciences (EW) Tops Q1 Earnings, Updates '17 View
by Zacks Equity Research
Edwards Lifesciences Corp. (EW) reported first-quarter 2017 adjusted earnings per share (EPS) of 94 cents, which surpassed the Zacks Consensus Estimate by 14.6%.
Baxter International (BAX) Q1 Earnings Beat, FY17 View Up
by Zacks Equity Research
Baxter International Inc. (BAX) reported first-quarter 2017 adjusted earnings of 58 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents and was way better than the year-ago figure of 36 cents.
NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.
LabCorp (LH) Tops Q1 Earnings, Misses on Sales, Tweaks View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported first-quarter 2017 adjusted earnings per share (EPS) of $2.22, up 8.3% from the year-ago quarter.
Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted first-quarter 2017 adjusted earnings per share of $1.33, beating the Zacks Consensus Estimate by a penny.
C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.
Baxter Launches Drug Library Guide for Smart Infusion System
by Zacks Equity Research
Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown
by Zacks Equity Research
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.
Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics' (DGX) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate.
Inogen, Avis Budget Group, Qualcomm, American Express and CSX highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Inogen, Avis Budget Group, Qualcomm, American Express and CSX highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Inogen (INGN)
by David Bartosiak
Medical devices offer a less volatile area of the biotech market
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device
by Zacks Equity Research
Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc.(ISRG) posted adjusted earnings of $4.67 per share in the first quarter of 2017, crushing the Zacks Consensus Estimate of $3.97 on stellar revenue growth.
GNC Holdings (GNC) Q1 Earnings & Revenues Top, Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported first-quarter 2017 adjusted earnings per share (EPS) of 37 cents, reflecting a massive 46.4% year-over-year deterioration.
Abbott Laboratories Agrees to Acquire Alere at Lower Price
by Zacks Equity Research
Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share upon the completion of the transaction.
Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it has received the FDA clearance for its Mazor X Align software.
Aetna (AET) Hurt by Exchange Business, High Medical Costs
by Zacks Equity Research
Shares of health insurer Aetna Inc. (AET) underperformed over the past one year.